Edwards said it plans to use the proceeds from the sale of the business to fund investments for growth, such as in technologies for aortic, mitral, tricuspid and pulmonic patients; and therapeutic areas for interventional heart failure.
Source: https://www.marketwatch.com/story/edwar ... topstories
Edwards Lifesciences to get $4.2 billion in cash for sale of critical-care group
